86 related articles for article (PubMed ID: 38678024)
1. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
3. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer.
Papakyriacou I; Kutkaite G; Rúbies Bedós M; Nagarajan D; Alford LP; Menden MP; Mao Y
Nat Commun; 2024 Apr; 15(1):3581. PubMed ID: 38678024
[TBL] [Abstract][Full Text] [Related]
4. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
5. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
7. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
8. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
9. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner CK; Ebrahimi-Nik H; Iracheta-Vellve A; Hamel KM; Olander KE; Davis TGR; McGuire KA; Halvorsen GT; Avila OI; Patel CH; Kim SY; Kammula AV; Muscato AJ; Halliwill K; Geda P; Klinge KL; Xiong Z; Duggan R; Mu L; Yeary MD; Patti JC; Balon TM; Mathew R; Backus C; Kennedy DE; Chen A; Longenecker K; Klahn JT; Hrusch CL; Krishnan N; Hutchins CW; Dunning JP; Bulic M; Tiwari P; Colvin KJ; Chuong CL; Kohnle IC; Rees MG; Boghossian A; Ronan M; Roth JA; Wu MJ; Suermondt JSMT; Knudsen NH; Cheruiyot CK; Sen DR; Griffin GK; Golub TR; El-Bardeesy N; Decker JH; Yang Y; Guffroy M; Fossey S; Trusk P; Sun IM; Liu Y; Qiu W; Sun Q; Paddock MN; Farney EP; Matulenko MA; Beauregard C; Frost JM; Yates KB; Kym PR; Manguso RT
Nature; 2023 Oct; 622(7984):850-862. PubMed ID: 37794185
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms driving the immunoregulatory function of cancer cells.
van Weverwijk A; de Visser KE
Nat Rev Cancer; 2023 Apr; 23(4):193-215. PubMed ID: 36717668
[TBL] [Abstract][Full Text] [Related]
11. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Torka P; Kambhampati S; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
[TBL] [Abstract][Full Text] [Related]
12. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
[TBL] [Abstract][Full Text] [Related]
13. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Adès L; Girshova L; Doronin VA; Díez-Campelo M; Valcárcel D; Kambhampati S; Viniou NA; Woszczyk D; De Paz Arias R; Symeonidis A; Anagnostopoulos A; Munhoz EC; Platzbecker U; Santini V; Fram RJ; Yuan Y; Friedlander S; Faller DV; Sekeres MA
Blood Adv; 2022 Sep; 6(17):5132-5145. PubMed ID: 35728048
[TBL] [Abstract][Full Text] [Related]
14. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Wolf DM; Yau C; Wulfkuhle J; Brown-Swigart L; Gallagher RI; Lee PRE; Zhu Z; Magbanua MJ; Sayaman R; O'Grady N; Basu A; Delson A; Coppé JP; Lu R; Braun J; ; Asare SM; Sit L; Matthews JB; Perlmutter J; Hylton N; Liu MC; Pohlmann P; Symmans WF; Rugo HS; Isaacs C; DeMichele AM; Yee D; Berry DA; Pusztai L; Petricoin EF; Hirst GL; Esserman LJ; van 't Veer LJ
Cancer Cell; 2022 Jun; 40(6):609-623.e6. PubMed ID: 35623341
[TBL] [Abstract][Full Text] [Related]
15. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.
Joung J; Kirchgatterer PC; Singh A; Cho JH; Nety SP; Larson RC; Macrae RK; Deasy R; Tseng YY; Maus MV; Zhang F
Nat Commun; 2022 Mar; 13(1):1606. PubMed ID: 35338135
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
